Arndt Vogel, MD

Arndt Vogel, MD, is a faculty member at the University of Toronto Institute of Medical Science, a scientist at the Toronto General Hospital Research Institute, and a medical oncologist at the UHN–Princess Margaret Cancer Centre

Articles by Arndt Vogel, MD

Treatment Options for Advanced HCC in the Second-Line and Beyond

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

November 4th 2022

Brief but comprehensive insight to the cornerstone second-line treatment options in the setting of recurrent advanced hepatocellular carcinoma.

Novel First-Line Immunotherapy Approaches in Advanced HCC

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

November 4th 2022

Panelists close out their discussion on first-line treatment options for advanced HCC with a review of single-agent and combination immunotherapy approaches.

Real-World Use of Durvalumab + Tremelimumab in Advanced HCC

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

October 28th 2022

In the context of clinical data from the HIMALAYA and STRIDE trials, expert oncologists review real-world use of tremelimumab + durvalumab in advanced HCC.

Patient Profile 2: A 70-Year-Old Man With Advanced HCC Treated With Durvalumab + Tremelimumab

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

October 28th 2022

Focusing on a second patient profile of advanced hepatocellular carcinoma, panelists consider the role of first-line tremelimumab + durvalumab.

Real-World Use of First-Line Lenvatinib Therapy in Advanced HCC

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

October 21st 2022

Comprehensive discussion on the real-world applications of first-line lenvatinib therapy in advanced HCC followed by its potential in combination with TACE.

Advanced HCC: Clinical Trial Data Behind First-Line Therapy Options

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

October 21st 2022

Expert oncologists take a look at clinical trial data as they pertain to prevalent first-line systemic therapy options in advanced hepatocellular carcinoma.

Selecting the Appropriate First-Line Therapy for Advanced HCC

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

October 14th 2022

In the context of the first patient profile, expert panelists consider which factors play into their selection of first-line systemic agents in advanced hepatocellular carcinoma.

Patient Profile 1: A 77-Year-Old Man with Advanced HCC Treated With Lenvatinib

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

October 14th 2022

Focusing on the first patient profile of advanced hepatocellular carcinoma, Andrea Casadei-Gardini, MD, reviews his selection and use of first-line lenvatinib therapy.

Advanced HCC: Updates in First-line Systemic Therapy

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

October 7th 2022

Moderator Josep Llovet, MD, centers discussion on advanced hepatocellular carcinoma and provides a broad overview of treatment options in the frontline setting.

Role of Systemic Therapy in Early- or Intermediate-Stage HCC

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

October 7th 2022

Expert perspectives on the selection and use of systemic therapy in patients who progress on or are unsuitable for locoregional therapies.

Role of Locoregional Therapy in Early- or Intermediate-Stage HCC

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

September 30th 2022

Comprehensive insight on the role of locoregional therapies in early- or intermediate-stage HCC, alone or in combination with systemic agents.

Early- and Intermediate-Stage HCC Treatment Landscape

ByJosep M. Llovet, MD, PhD,Andrea Casadei Gardini, MD, San Raffaele Research Hospital,Katie Kelley, MD,Amit Singal, MD, MS,Arndt Vogel, MD

September 30th 2022

Opening their discussion on the management of hepatocellular carcinoma, expert panelists take a broad look at the treatment landscape.

The Evolving Treatment Landscape of HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 24th 2022

Closing out their discussion on hepatocellular carcinoma, expert panelists consider future directions in care.

Later-Line IO Therapy for Advanced Hepatocellular Carcinoma

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 17th 2022

Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.

Selecting Therapy for Advanced HCC Following Atezo-Bev Failure

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 17th 2022

Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Selecting Therapy for Advanced HCC Following TKI Failure

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 10th 2022

Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.

Patient Profile 3: Second-Line Therapy for Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 10th 2022

Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.

Frontline Therapy for Advanced HCC: Novel Combination Strategies

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 3rd 2022

Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.

Frontline Lenvatinib versus Sorafenib Treatment in Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

August 3rd 2022

Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.

Role of Hepatitis Status in Selecting Therapy for HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 27th 2022

Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.

Real-World Selection of Frontline Combination Therapy for Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 27th 2022

Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.

HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 20th 2022

Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.

Patient Profile 2: Frontline Therapy for Advanced HCC

ByTanios S. Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 20th 2022

Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.

Management of HCC: Advances in Biomarkers and Screening

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 13th 2022

A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.

Selection and Use of Systemic Therapy in Intermediate Stage HCC

ByTanios Bekaii-Saab, MD,Anthony El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 13th 2022

Panelists consider the role of systemic therapy in patients with intermediate-stage HCC who are ineligible for locoregional therapy.

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

ByTanios Bekaii-Saab, MD,Anthony B. El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 6th 2022

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

Early-Stage HCC: What is the Role of Neoadjuvant Therapy?

ByTanios Bekaii-Saab, MD,Anthony B. El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

July 6th 2022

Expert oncologists consider when it would be appropriate to use neoadjuvant therapy for early-/intermediate-stage hepatocellular carcinoma.

Dr. Vogel on the OS Benefit of Durvalumab/Tremelimumab in Unresectable HCC

ByArndt Vogel, MD

June 30th 2022

Arndt Vogel, MD, discusses the outcomes of the phase 3 HIMALAYA trial in unresectable hepatocellular carcinoma.

Early-Stage HCC: Role of Adjuvant Therapy

ByTanios Bekaii-Saab, MD,Anthony B. El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

June 29th 2022

A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.

Patient Profile 1: Resection for Early/Intermediate Stage HCC

ByTanios Bekaii-Saab, MD,Anthony B. El-Khoueiry, MD,Pierre Gholam, MD,Arndt Vogel, MD,Mark Yarchoan, MD

June 29th 2022

Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.

Arndt Vogel, MD

Articles by Arndt Vogel, MD

Treatment Options for Advanced HCC in the Second-Line and Beyond

Novel First-Line Immunotherapy Approaches in Advanced HCC

Real-World Use of Durvalumab + Tremelimumab in Advanced HCC

Patient Profile 2: A 70-Year-Old Man With Advanced HCC Treated With Durvalumab + Tremelimumab

Real-World Use of First-Line Lenvatinib Therapy in Advanced HCC

Advanced HCC: Clinical Trial Data Behind First-Line Therapy Options

Selecting the Appropriate First-Line Therapy for Advanced HCC

Patient Profile 1: A 77-Year-Old Man with Advanced HCC Treated With Lenvatinib

Advanced HCC: Updates in First-line Systemic Therapy

Role of Systemic Therapy in Early- or Intermediate-Stage HCC

Role of Locoregional Therapy in Early- or Intermediate-Stage HCC

Early- and Intermediate-Stage HCC Treatment Landscape

The Evolving Treatment Landscape of HCC

Later-Line IO Therapy for Advanced Hepatocellular Carcinoma

Selecting Therapy for Advanced HCC Following Atezo-Bev Failure

Selecting Therapy for Advanced HCC Following TKI Failure

Patient Profile 3: Second-Line Therapy for Advanced HCC

Frontline Therapy for Advanced HCC: Novel Combination Strategies

Frontline Lenvatinib versus Sorafenib Treatment in Advanced HCC

Role of Hepatitis Status in Selecting Therapy for HCC

Real-World Selection of Frontline Combination Therapy for Advanced HCC

HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC

Patient Profile 2: Frontline Therapy for Advanced HCC

Management of HCC: Advances in Biomarkers and Screening

Selection and Use of Systemic Therapy in Intermediate Stage HCC

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

Early-Stage HCC: What is the Role of Neoadjuvant Therapy?

Dr. Vogel on the OS Benefit of Durvalumab/Tremelimumab in Unresectable HCC

Early-Stage HCC: Role of Adjuvant Therapy

Patient Profile 1: Resection for Early/Intermediate Stage HCC

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies